Free Trial

FS Development (FSDC) Competitors

Notice: This company has been marked as potentially delisted and may not be actively trading.

FSDC vs. LSEA, YSAC, GWAC, GLEO, NAMS, KROS, HRMY, SNDX, EWTX, and PTGX

Should you be buying FS Development stock or one of its competitors? The main competitors of FS Development include Landsea Homes (LSEA), Yellowstone Acquisition (YSAC), Good Works Acquisition (GWAC), Galileo Acquisition (GLEO), NewAmsterdam Pharma (NAMS), Keros Therapeutics (KROS), Harmony Biosciences (HRMY), Syndax Pharmaceuticals (SNDX), Edgewise Therapeutics (EWTX), and Protagonist Therapeutics (PTGX).

FS Development vs.

Landsea Homes (NASDAQ:LSEA) and FS Development (NASDAQ:FSDC) are both small-cap finance companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation, earnings, dividends and community ranking.

83.0% of Landsea Homes shares are held by institutional investors. Comparatively, 89.8% of FS Development shares are held by institutional investors. 51.0% of Landsea Homes shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Landsea Homes presently has a consensus price target of $13.75, suggesting a potential upside of 40.31%. Given FS Development's higher probable upside, equities analysts clearly believe Landsea Homes is more favorable than FS Development.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Landsea Homes
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75
FS Development
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Landsea Homes has higher revenue and earnings than FS Development.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Landsea Homes$1.21B0.29$29.24M$0.6814.41
FS DevelopmentN/AN/AN/AN/AN/A

Landsea Homes received 18 more outperform votes than FS Development when rated by MarketBeat users.

CompanyUnderperformOutperform
Landsea HomesOutperform Votes
18
36.73%
Underperform Votes
31
63.27%
FS DevelopmentN/AN/A

Landsea Homes has a net margin of 2.08% compared to Landsea Homes' net margin of 0.00%. FS Development's return on equity of 6.17% beat Landsea Homes' return on equity.

Company Net Margins Return on Equity Return on Assets
Landsea Homes2.08% 6.17% 2.90%
FS Development N/A N/A N/A

In the previous week, Landsea Homes had 4 more articles in the media than FS Development. MarketBeat recorded 4 mentions for Landsea Homes and 0 mentions for FS Development. FS Development's average media sentiment score of 0.49 beat Landsea Homes' score of 0.00 indicating that Landsea Homes is being referred to more favorably in the media.

Company Overall Sentiment
Landsea Homes Neutral
FS Development Neutral

Summary

Landsea Homes beats FS Development on 10 of the 11 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FSDC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FSDC vs. The Competition

MetricFS DevelopmentPharmaceutical Preparations IndustryMedical SectorNASDAQ Exchange
Market Cap$453.83M$7.05B$5.14B$7.99B
Dividend YieldN/A2.67%2.79%4.00%
P/E RatioN/A16.69159.7316.92
Price / SalesN/A246.882,419.0674.30
Price / CashN/A19.7831.9129.00
Price / BookN/A5.995.074.41
Net IncomeN/A$145.28M$108.07M$215.19M

FS Development Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LSEA
Landsea Homes
4.0463 of 5 stars
$9.92
+2.2%
$13.75
+38.6%
+35.0%$351.48M$1.21B14.59497Gap Up
YSAC
Yellowstone Acquisition
0 of 5 stars
N/AN/AN/A$147.38MN/A0.003
GWAC
Good Works Acquisition
0 of 5 stars
$3.71
-1.3%
N/A+41.1%$79.68MN/A0.002High Trading Volume
GLEO
Galileo Acquisition
0 of 5 stars
$1.02
-1.9%
N/A+102.0%$17.75MN/A0.002Gap Up
NAMS
NewAmsterdam Pharma
3.6313 of 5 stars
$18.75
+1.2%
$33.25
+77.3%
+37.4%$1.69B$6.86M0.0029Positive News
High Trading Volume
KROS
Keros Therapeutics
1.7633 of 5 stars
$46.87
+1.2%
$86.00
+83.5%
-1.0%$1.67B$150,000.00-9.10141Positive News
HRMY
Harmony Biosciences
3.8971 of 5 stars
$29.40
+1.8%
$40.63
+38.2%
-14.8%$1.64B$582.02M12.73246Short Interest ↑
News Coverage
SNDX
Syndax Pharmaceuticals
3.7422 of 5 stars
$19.27
-0.1%
$34.42
+78.6%
-5.7%$1.64B$139.71M-5.98184Positive News
EWTX
Edgewise Therapeutics
1.6601 of 5 stars
$17.13
-2.1%
$31.20
+82.1%
+79.5%$1.63BN/A-11.0592Positive News
PTGX
Protagonist Therapeutics
2.9268 of 5 stars
$28.15
+1.6%
$38.00
+35.0%
+5.7%$1.63B$60M11.54112

Related Companies and Tools

This page (NASDAQ:FSDC) was last updated on 6/4/2024 by MarketBeat.com Staff

From Our Partners